[Expression of cancer-related indices in different types of cystitis glandularis and clinical significance thereof].
OBJECTIVE
To explore the rationality of clinical typing of cystitis glandularis (CG) and the potential of cancerization of different types of CG.


METHODS
Flow cytometry was performed to examine the ploidy of 25 fresh bladder specimens of patients with CG resected during operation, 13 high risk type and 12 low risk type, and 7 specimens of normal mucosa of bladder, by calculating the DNA index (DI). Immunohistochemistry was used to detect the expression of proliferating cell nuclear antigen (PCNA), mutant p53, p21ras, Rb, and bcl-2 in other 38 preserved specimens of CG resected during operation, 18 high risk type and 20 low risk type, and 5 specimens of normal bladder.


RESULTS
The DI was 1.00 +/- 0.03 in the normal bladder group, 1.05 +/- 0.07 in the high risk type CG group, and 1.01 +/- 0.05 in the low risk type CG, without significant differences between any 2 groups (t = -1.639, P = 0.115). The expression of PCNA and expression of p53 were negative in the low risk group, and PCNA was expressed in 5 specimens of high risk type CG (27.8%), and not expressed in the low risk type CG (P = 0.017). p53 was expressed in 4 specimens of high risk type CG (22.2%), and not expressed in the low risk type CG (P = 0.041). There were no significant differences in the expression of p21, Rb, and bcl-2 between the high and low risk groups.


CONCLUSIONS
High risk type and low risk type of CG are both benign lesions. High risk type CG may be more likely to cancerate. It is reasonable to distinguish different types of CG. p53 gene may play an important role in the canceration of CG.
Chen
Zhi-qiang
ZQ
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Wei
Zhi-feng
ZF
Ye
Zhang-qun
ZQ
Yang
Wei-min
WM
D003556:Cystitis / Q000145:classification / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D001743:Urinary Bladder / Q000378:metabolism / Q000473:pathology*
D018809:Proliferating Cell Nuclear Antigen; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53